Armenian Translation

Are You at Risk for Peripheral Arterial Disease?

Today announced that CCX140, the Company’s novel, orally active CCR2 antagonist effectively met its major endpoint of protection and tolerability and demonstrated medical efficacy in a Phase II study in sufferers with type 2 diabetes on stable dosages of metformin. Related StoriesDiabetes avoidance begins in the wombMayo Clinic investigators discover novel system linked to diabetes riskStudy suggests need for specific treatment plans for adolescents with onset type 2 diabetes We have become pleased with the good results attained by administering CCX140 in type 2 diabetics, since this is the population where we plan to further evaluate the drug in a Stage II trial in sufferers with diabetic nephropathy, stated Thomas J. Schall, Ph.D., Chief and President Executive Officer of ChemoCentryx.The Stage 2 AdV HALT Trial can be a randomized, placebo-controlled study intended to measure the protection and efficacy of preemptive treatment with CMX001 to be able to prevent immunocompromised pediatric and adult sufferers with asymptomatic adenovirus illness from developing disease. In immunocompromised patients, including those who have undergone HSCT, adenovirus infections are named a significant reason behind morbidity and mortality. ‘It really is well known that this population is much less tolerant of the toxicities associated with conventional antiviral medications, especially the kidney toxicity connected with cidofovir, and we wish CMX001 can make a significant difference.’ ‘We believe CMX001’s quickly evolving antiviral and security profile provides solid support because of this candidate’s broad-spectrum, preemptive usage, which includes the often-overlooked pediatric populace,’ said Kenneth I.